OncoMatch/Clinical Trials/NCT07707531
A Study to Evaluate the Human Biodistribution and Dosimetry of the Radionuclide Labeled IR199 in Patients With Gastric Cancer and Pancreatic Cancer
Is NCT07707531 recruiting? Yes, currently enrolling (Sep 2026). This Early Phase 1 trial studies [68Ga]/ [131I]-IR199 for gastric cancer.
Treatment: [68Ga]/ [131I]-IR199 — This study is to evaluate the safety, biodistribution, radiation dosimetry and tumor uptake of the \[68Ga\]/ \[131I\]-IR199 in patients with Claudin 18.2 positive gastric cancer and pancreatic cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Gastric Cancer
Pancreatic Cancer
Biomarker criteria
Required: CLDN18 expression
gastric cancer or pancreatic cancer with Claudin 18.2 expression
Required: CLDN18 expression (positive)
Must have ≥1 Claudin 18.2 positive lesions
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07707531 currently recruiting?
Yes, this trial is currently recruiting patients.
Does this trial require CLDN18?
Yes, CLDN18 expression is a required biomarker for enrollment.
Does this trial require CLDN18?
Yes, CLDN18 expression is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages